Topline Phase 3 TRIUMPH-1 trial results show retatrutide drives a 30.3 percent body weight loss over 104 weeks of treatment.
AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population.Randomization ...
MSN on MSN
Enliven Therapeutics reports positive phase 1 CML data and FDA alignment for phase 3 trial (ELVN)
Updated ELVN-001 results showed strong molecular response rates in previously treated CML patients, while the FDA aligned ...
(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without ...
DUBLIN, March 3, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the ...
Vietnam Investment Review on MSN
Menarini reports phase 3 SENTRY trial data on selinexor plus ruxolitinib in myelofibrosis at EHA 2026
FLORENCE, Italy and NEW YORK, June 14, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline" ...
New York, NY (November 25, 2025) – An international team of investigators led by Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of ...
Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
Zenas BioPharma is rated a buy ahead of the pivotal INDIGO Phase 3 trial readout for obexelimab in IgG4-RD, expected by year-end. ZBIO's strong balance sheet, with $301.6M in cash and runway into late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results